Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histology/cytology confirmed Transitional Cell Carcinoma (TCC) with locally advanced (T4b) or metastatic urothelial tract or bladder cancer
ECOG Performance Status 0 or 1
No prior palliative chemotherapy
You may not be if
(Neo)Adjuvant chemotherapy if \< 6 months between end of (neo)adjuvant chemotherapy and relapse
Less than 6 weeks elapsed from prior radiotherapy and less than 3 weeks from surgery to time of randomization
Prior cisplatin as (neo)adjuvant chemotherapy with cumulative dose \> 300 mg/m²
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
